{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:33:39Z","timestamp":1792215219248,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007004.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T00:00:00Z","timestamp":1398729600000}}],"reference-count":108,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007004.pub3","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T11:06:40Z","timestamp":1398769600000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Aldosterone antagonists for preventing the progression of chronic kidney disease"],"prefix":"10.1002","author":[{"given":"Davide","family":"Bolignano","sequence":"first","affiliation":[{"name":"CNR - Italian National Council of Research; Institute of Clinical Physiology; CNR-IFC Via Vallone Petrara c\/o Ospedali Riuniti Reggio Calabria Italy 89100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar D","family":"Navaneethan","sequence":"additional","affiliation":[{"name":"Glickman Urological and Kidney Institute, Cleveland Clinic; Department of Nephrology and Hypertension; Cleveland OH USA 44195"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"},{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy 70100"},{"name":"Mario Negri Sud Consortium; Department of Clinical Pharmacology and Epidemiology; Santa Maria Imbaro Italy"},{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"},{"name":"Diaverum; Medical-Scientific Office; Lund Sweden. Amedeo Avogadro University of Eastern Piedmont; Division of Nephrology and Transplantation, Department of Translational Medicine; Novara Italy 28100"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,29]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD007004.pub3-BIB0001|cit1","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD007004.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1053\/j.ajkd.2009.11.006","article-title":"Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases","volume":"55","author":"Bianchi","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"12","key":"10.1002\/14651858.CD007004.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney International"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007004.pub3-BIB0004|cit4","first-page":"33A","article-title":"Spironolactone reduces proteinuria and retards the progression of kidney disease: a long-term study [abstract no: TH-FC152]","volume":"17","author":"Bianchi","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD007004.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"e26904","DOI":"10.1371\/journal.pone.0026904","article-title":"Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study","volume":"6","author":"Boesby","year":"2011","journal-title":"PLoS ONE"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007004.pub3-BIB0006|cit6","first-page":"ii882","article-title":"Aldosterone blockade in patients with non-diabetic chronic kidney disease [abstract no: SA153]","volume":"2","author":"Boesby","year":"2009","journal-title":"NDT Plus"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007004.pub3-BIB0007|cit7","first-page":"A137","article-title":"A double blind, placebo controlled study on the effect of the aldosterone receptor blocker: spironolactone, in patients with persistent proteinuria on longterm ACE inhibitor therapy, with or without an ATRB [abstract no: T-PO20016]","volume":"10","author":"Chrysostomou","year":"2005","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007004.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","article-title":"Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007004.pub3-BIB0009|cit9","first-page":"936A","article-title":"Discordant changes in vascular compliance and proteinuria with drug therapy in CKD patients [abstract no: PUB556]","volume":"21","author":"Cohen","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007004.pub3-BIB0010|cit10","first-page":"A116","article-title":"Addition of eplerenone to RAAS blockade in patients with CKD and proteinuria correlates with baseline vascular compliance [abstract no: PO247]","volume":"13","author":"Cohen","year":"2011","journal-title":"Journal of Clinical Hypertension"},{"issue":"10","key":"10.1002\/14651858.CD007004.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.amjcard.2010.07.018","article-title":"Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease","volume":"106","author":"Edwards","year":"2010","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","article-title":"The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease","volume":"73","author":"Edwards","year":"2012","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD007004.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1365-2265.2010.03832.x","article-title":"The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease","volume":"73","author":"Hammer","year":"2010","journal-title":"Clinical Endocrinology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007004.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","article-title":"Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract no: OR54]","volume":"15","author":"Epstein","year":"2002","journal-title":"American Journal of Hypertension"},{"issue":"Nov","key":"10.1002\/14651858.CD007004.pub3-BIB0016|cit16","first-page":"6A","article-title":"The selective aldosterone blocker eplerenone reduces proteinuria without concomitant hyperkalemia [abstract no: F-FC026]","volume":"14","author":"Epstein","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007004.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD007004.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","article-title":"Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker","volume":"31","author":"Furumatsu","year":"2008","journal-title":"Hypertension Research"},{"key":"10.1002\/14651858.CD007004.pub3-BIB0019|cit19","first-page":"58A","article-title":"Antiproteiuric effect of triple blockade with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone; one year follow up [abstract no: SU-FC069]","volume":"15","author":"Furumatsu","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl S","key":"10.1002\/14651858.CD007004.pub3-BIB0020|cit20","first-page":"762A","article-title":"Antiproteinuric effect of triple blockage with angiotensin-converting-enzyme inhibitor, angiotensin-II receptor blocker and spironolactone [abstract no: SU-PO1031]","volume":"14","author":"Furumatsu","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD007004.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/08860220903150312","article-title":"Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease","volume":"31","author":"Guney","year":"2009","journal-title":"Renal Failure"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD007004.pub3-BIB0022|cit22","first-page":"vi257","article-title":"The effects of aldosterone blockade on proteinuria and glomerular filtration rate in patients with chronic kidney disease [abstract no: SAP075]","volume":"22","author":"Haykal","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007004.pub3-BIB0023|cit23","first-page":"iii424","article-title":"Combination of angiotensin converting enzyme inhibitors with mineralocorticoid antagonists in diabetic nephropathy [abstract no: SU342]","volume":"3","author":"Koroshi","year":"2010","journal-title":"NDT Plus"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007004.pub3-BIB0024|cit24","first-page":"ii1029","article-title":"Change of proteinuria after adding spironolactone ACE inhibitor or angiotensin receptor blockers in IGA nephropathy, a pilot study [abstract no: SA309]","volume":"2","author":"Lv","year":"2009","journal-title":"NDT Plus"},{"issue":"12","key":"10.1002\/14651858.CD007004.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007004.pub3-BIB0026|cit26","first-page":"28A","article-title":"Effect of an angiotensin receptor blocker (ARB) or a mineralocorticoid antagonist (MRA) added-on to maximally-dosed angiotensin converting enzyme inhibitor (ACEi) regimen in diabetic nephropathy (DN) [abstract no: TH-FC128]","volume":"19","author":"Mehdi","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD007004.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2310\/JIM.0b013e3181ff46a5","article-title":"Effective antihypertensive strategies for high-risk patients with diabetic nephropathy","volume":"58","author":"Buren","year":"2010","journal-title":"Journal of Investigative Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007004.pub3-BIB0028|cit28","first-page":"421","article-title":"The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective?","volume":"29","author":"Morales","year":"2009","journal-title":"Nefrologia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007004.pub3-BIB0029|cit29","first-page":"ii882","article-title":"Antiproteinuric effect of Renin-Angiotensin-Aldosterone System (RAAS) in obese patients. Which is the most effective option? [abstract no: SA131]","volume":"2","author":"Morales","year":"2009","journal-title":"NDT Plus"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007004.pub3-BIB0030|cit30","first-page":"549A","article-title":"Antiproteinuric effect of renin-angiotensin-aldosterone system (RAAS) in obese patients. Which is the most effective option? [abstract no: F-PO1941]","volume":"19","author":"Morales","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007004.pub3-BIB0031|cit31","first-page":"S445","article-title":"Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: A randomised placebo-controlled crossover study [abstract no: 1099]","volume":"54","author":"Nielsen","year":"2011","journal-title":"Diabetologia"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007004.pub3-BIB0032|cit32","first-page":"238A","article-title":"Spironolactone diminishes urinary albumin excretion in type 1 diabetic patients with microalbuminuria: a randomized placebo-controlled crossover study [abstract no: TH-PO548]","volume":"22","author":"Nielsen","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD007004.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabetic Medicine"},{"issue":"5-6","key":"10.1002\/14651858.CD007004.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1440-1681.2006.04390.x","article-title":"Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor","volume":"33","author":"Ogawa","year":"2006","journal-title":"Clinical & Experimental Pharmacology & Physiology"},{"issue":"9","key":"10.1002\/14651858.CD007004.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007004.pub3-BIB0036|cit36","first-page":"157A","article-title":"Spironolactone reduces proteinuria further in diabetic patients who are already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind cross-over trial [abstract no: TH-PO240]","volume":"17","author":"Saklayen","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007004.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","article-title":"Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial","volume":"56","author":"Saklayen","year":"2008","journal-title":"Journal of Investigative Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD007004.pub3-BIB0039|cit39","first-page":"57A","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy [abstract no: F-FC090]","volume":"16","author":"Schjoedt","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007004.pub3-BIB0041|cit41","first-page":"iv386","article-title":"Contrasting effects of spironolactone and hydrochlorothiazide in patients with persistent glomerular proteinuria [abstract no: MP260]","volume":"21","author":"Smolen","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD007004.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.metabol.2006.07.025","article-title":"The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy","volume":"55","author":"Matsumoto","year":"2006","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1210\/jc.2005-1718","article-title":"Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy","volume":"91","author":"Takebayashi","year":"2006","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007004.pub3-BIB0044|cit44","first-page":"525A","article-title":"Add-on spironolactone in patients with advanced chronic kidney disease treated with angiotensin II receptor blockers [abstract no: F-PO1840]","volume":"19","author":"Tokunaga","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD007004.pub3-BIB0045|cit45","first-page":"vi259","article-title":"The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SAP081]","volume":"22","author":"Larczynski","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial","volume":"52","author":"Tylicki","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"9","key":"10.1002\/14651858.CD007004.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/sj.ki.5002511","article-title":"Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney","volume":"72","author":"Tylicki","year":"2007","journal-title":"Kidney International"},{"issue":"11","key":"10.1002\/14651858.CD007004.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"Meiracker","year":"2006","journal-title":"Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD007004.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5428\/pcar20110408","article-title":"Clinical investigation of combined therapy with benazepril and spironolactone in diabetic nephropathy","volume":"11","author":"Zheng","year":"2011","journal-title":"Pharmaceutical Care & Research"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007004.pub3-BIB0050|cit50","first-page":"322A","article-title":"Eplerenone, a new selective aldosterone receptor antagonist (SARA): efficacy in patients with mild to moderate hypertension [abstract no: A1640]","volume":"9","author":"Epstein","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD007004.pub3-BIB0051|cit51","first-page":"vi322","article-title":"The influence of spironolactone on plasma level of plasminogen-activator inhibitor type 1 (PAI-1) in anuric hemodialysis patients [abstract no: SaP266]","volume":"22","author":"Essaian","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD007004.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1291\/hypres.27.963","article-title":"Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy","volume":"27","author":"Horita","year":"2004","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007004.pub3-BIB0053|cit53","first-page":"A37","article-title":"Aldosterone breakthrough during combined angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in patients with IgA nephropathy [abstract no: M-PO20083]","volume":"10","author":"Horita","year":"2005","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007004.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2006.00665.x","article-title":"Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy","volume":"11","author":"Horita","year":"2006","journal-title":"Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD007004.pub3-BIB0055|cit55","first-page":"1808","article-title":"Aldosterone blockade in children with chronic allograft nephropathy [abstract]","volume":"25","author":"Medeiros","year":"2010","journal-title":"Pediatric Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007004.pub3-BIB0056|cit56","first-page":"411","article-title":"Aldosterone blockade in children with chronic allograft nephropathy [abstract no: 1296]","volume":"10","author":"Medeiros","year":"2010","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD007004.pub3-BIB0057|cit57","first-page":"71","article-title":"Mineralocorticoid receptor blockade in children with chronic allograft injury [abstract]","volume":"17","author":"Medeiros","year":"2013","journal-title":"Pediatric Transplantation"},{"key":"10.1002\/14651858.CD007004.pub3-BIB0058|cit58","first-page":"98","article-title":"Aldosterone blockade in children with chronic allograft nephropathy [abstract]","volume":"15","author":"Medeiros","year":"2011","journal-title":"Pediatric Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD007004.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/HYPERTENSIONAHA.108.125252","article-title":"Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease","volume":"53","author":"Preston","year":"2009","journal-title":"Hypertension"},{"issue":"7","key":"10.1002\/14651858.CD007004.pub3-BIB0060|cit60","first-page":"818","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. [Retraction of Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, Ravid M. Diabet Med. 2004 May;21(5):471-5; PMID: 15089793]","volume":"23","author":"Anonymous","year":"2006","journal-title":"Diabetic Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007004.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabetic Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007004.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1161\/HYPERTENSIONAHA.108.120568","article-title":"spironolactone attenuates oxidative stress in patients with chronic kidney disease","volume":"52","author":"Renke","year":"2008","journal-title":"Hypertension"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007004.pub3-BIB0063|cit63","first-page":"iii35","article-title":"Is eplerenone a safe and effective antiproteinuric drug in elderly patients with stage 3 chronic kidney disease (CKD)? [abstract no: Sa026]","volume":"3","author":"Rosado Rubio","year":"2010","journal-title":"NDT Plus"},{"issue":"11","key":"10.1002\/14651858.CD007004.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1093\/ndt\/gfp311","article-title":"Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial","volume":"24","author":"Schjoedt","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007004.pub3-BIB0065|cit65","first-page":"953A","article-title":"Autoregulation of the glomerular filtration rate during spironolactone treatment [abstract no: PUB561]","volume":"18","author":"Schjoedt","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007004.pub3-BIB0066|cit66","first-page":"60A","article-title":"Low dose spironolactone rapidly reduces left ventricular mass [abstract no: F-FC099]","volume":"16","author":"Schmidt","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract-Band","key":"10.1002\/14651858.CD007004.pub3-BIB0067|cit67","first-page":"68","article-title":"Effects of aldosterone on kidney blood flow","volume":"100","author":"Schmidt","year":"2005","journal-title":"Medizinische Klinik"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007004.pub3-BIB0068|cit68","first-page":"617A","article-title":"Eplerenone at low dose induces regression of left ventricular hypertrophy in resistant hypertension [abstract no: SA-PO2251]","volume":"19","author":"Schmidt","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007004.pub3-BIB0069|cit69","first-page":"iii427","article-title":"Spironolactone effect on preventing proteinuria in chronic kidney disease [abstract no: Su354]","volume":"3","author":"Shahbazian","year":"2010","journal-title":"NDT Plus"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007004.pub3-BIB0070|cit70","first-page":"33A","article-title":"A double blind randomized crossover trial of amiloride and spironolactone in black hypertensives with and without the T594M b-subunit epithelial sodium channel polymorphism [abstract no: TH-FC153]","volume":"17","author":"Swift","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD007004.pub3-BIB0071|cit71","first-page":"vi145","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function [abstract no: FP379]","volume":"22","author":"Mortazavi","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub3-BIB0072|cit72","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"key":"10.1002\/14651858.CD007004.pub3-BIB0073|cit73","first-page":"908A","article-title":"Combined blockade with the renin-angiotensin-aldosterone system to improve outcomes in diabetics with nephropathy (DN) [abstract no: PUB582]","volume":"16","author":"Toto","year":"2005","journal-title":"Journal of the American Society"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"European Journal of Heart Failure"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/hr.2010.46","article-title":"Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria","volume":"33","author":"Ando","year":"2010","journal-title":"Hypertension Research - Clinical & Experimental"},{"key":"10.1002\/14651858.CD007004.pub3-BIB0076|cit76","unstructured":"NCT00315016 Eplerenone, ACE inhibition and albuminuria www.clinicaltrials.gov\/ct2\/show\/NCT00315016"},{"key":"10.1002\/14651858.CD007004.pub3-BIB0077|cit77","unstructured":"Espinoza FG Effect of aldosterone antagonism in the reduction of albuminuria and diastolic disfunction of patients with diabetic nephropathy www.clinicaltrials.gov\/ct2\/show\/NCT00870402"},{"issue":"11","key":"10.1002\/14651858.CD007004.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1681\/ASN.2004090804","article-title":"Regression of existing glomerulosclerosis by inhibition of aldosterone","volume":"16","author":"Aldigier","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD007004.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007004.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1046\/j.1523-1755.2003.t01-2-00052.x","article-title":"Retarding the progression of renal disease","volume":"64","author":"Brenner","year":"2003","journal-title":"Kidney International"},{"issue":"17","key":"10.1002\/14651858.CD007004.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD007004.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11906-003-0012-2","article-title":"Aldosterone: a risk factor for vascular disease","volume":"5","author":"Fritsch Neves","year":"2003","journal-title":"Current Hypertension Reports"},{"issue":"9069","key":"10.1002\/14651858.CD007004.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","year":"1997","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD007004.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1093\/ndt\/gfi159","article-title":"ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends","volume":"20","author":"Grassmann","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD007004.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"Journal of Clinical Investigation"},{"issue":"7414","key":"10.1002\/14651858.CD007004.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007004.pub3-BIB0087|cit87","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"9","key":"10.1002\/14651858.CD007004.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","article-title":"Aldosterone in chronic kidney and cardiac disease","volume":"14","author":"Hostetter","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007004.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1002\/14651858.CD007004.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007004.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National\u00a0Kidney\u00a0Foundation\u00a0practice\u00a0guidelines\u00a0for\u00a0chronic\u00a0kidney\u00a0disease:\u00a0evaluation, classification and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"7201","key":"10.1002\/14651858.CD007004.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bmj.319.7201.24","article-title":"Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria","volume":"319","author":"Mathiesen","year":"1999","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"F628","DOI":"10.1152\/ajprenal.00524.2007","article-title":"Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome","volume":"294","author":"Nakhoul","year":"2008","journal-title":"American Journal of Physiology - Renal Physiology"},{"key":"10.1002\/14651858.CD007004.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/VHRM.S13779","article-title":"Aldosterone\u00a0and\u00a0aldosterone\u00a0receptor\u00a0antagonists\u00a0in patients with chronic heart failure","volume":"7","author":"Nappi","year":"2011","journal-title":"Vascular Health & Risk Management"},{"issue":"15","key":"10.1002\/14651858.CD007004.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Teo","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD007004.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips","year":"2007","journal-title":"Archives of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD007004.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD007004.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"Zeeuw","year":"2004","journal-title":"Kidney International"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD007004.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD007004.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1046\/j.1523-1755.2003.00340.x","article-title":"The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises","volume":"64","author":"Schieppati","year":"2003","journal-title":"Kidney International"},{"issue":"9","key":"10.1002\/14651858.CD007004.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1074\/jbc.273.9.4883","article-title":"Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation","volume":"273","author":"Silvestre","year":"1998","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"Journal of Endocrinology"},{"issue":"10","key":"10.1002\/14651858.CD007004.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1681\/ASN.2004080634","article-title":"Antihypertensive agents for primary prevention of diabetic nephropathy","volume":"16","author":"Strippoli","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007004.pub3-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006257","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease","author":"Strippoli","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007004.pub3-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","author":"Navaneethan","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007004.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007004.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD007004.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:06:13Z","timestamp":1628532373000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007004.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,4,29]]},"references-count":108,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007004.pub3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718369600.793495490","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,29]]}}}